DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Jared Holz - 4 it’s - 1 Eli Lilly - 1 Melissa Lee - 1 There's - 1 Biogen - 1 Trent - 1 medtech - 1
Top related locs:
Mizuho Securities America U.S Alphinity medtech
Top related orgs:
Mizuho Securities - 3 Novo Nordisk - 1 Citi Global Wealth Investments - 1 U.S . Healthcare - 1 Citi - 1 Biomea - 1 Alnylam Pharmaceuticals - 1 Mizuho Securities Americas - 1

Search resuls for: "Mizuho Securities America"


4 mentions found


☆ Mizuho’s Jared Holz breaks down UnitedHealth's Q1 earnings
  + stars: | 2024-04-16 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMizuho’s Jared Holz breaks down UnitedHealth's Q1 earningsJared Holz, Mizuho Securities America healthcare equity strategist, joins 'Squawk Box' to break down UnitedHealth's Q1 earnings. The health insurance giant posted first-quarter revenue that beat expectations.
Persons: Jared Holz Organizations: Mizuho Securities
☆ Mizuho's Jared Holz on finding opportunities in the biotech space
  + stars: | 2024-03-06 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMizuho's Jared Holz on finding opportunities in the biotech spaceJared Holz, Mizuho Securities America healthcare equity strategist, joins 'The Exchange' to discuss why he believes we are in the midst of the most pronounced biotech rally in over five years, whether it’s too late to get in on the trade, and more.
Persons: Jared Holz, it’s Organizations: Mizuho Securities
☆ Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz
  + stars: | 2024-02-29 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared HolzCNBC’s Melissa Lee and Jared Holz, Mizuho Securities America healthcare sector strategist, join 'Squawk on Street' to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk will remain the frontrunners for the next 2-3 years, and more.
Persons: Eli Lilly, Jared Holz, Melissa Lee Organizations: Novo Nordisk, Mizuho Securities Locations: Mizuho Securities America
☆ 'A trove of rebound opportunities': Strategists turn bullish on biotech and more, picking top stocks
  + stars: | 2024-01-17 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +4 min
2023 wasn't a good year for the health-care sector, but some investors expect it to make a comeback this year — highlighting biotech and medical tech as areas to watch. But now, Citi believes that "astute investors may find themselves with a trove of rebound opportunities." Citi's top picks in biotech include Biomea Fusion , Alnylam Pharmaceuticals , and Immunovant . Jared Holz, health-care sector strategist at Mizuho Securities Americas, named biotech firm Biogen as one of his top trading ideas for 2024. "Biotech has commanded everyone's attention, but the recovery of many best-in-class medical device companies post the GLP-1 selloff has been remarkable," Orton said.
Persons: There's, Jared Holz, Biogen, Trent, medtech, Matt Orton, Orton Organizations: Citi Global Wealth Investments, U.S . Healthcare, Citi, Biomea, Alnylam Pharmaceuticals, Mizuho Securities Americas, Biogen, medtech, Raymond James Investment Management, Medical, Biotech, Abbott Laboratories Locations: U.S, Alphinity, medtech
0 next >>
Total: 4